Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5935403 | 0.99 | MAOB (0.57) | MAOBKDM4EALDH1A1SMN1; SMN2ESR1 | |
| SCHEMBL4235138 | 0.91 | MAOB (0.60) | MAOBKDM4EALDH1A1SMN1; SMN2ESR1 | |
| Hydrochloric Acid SCHEMBL5935401 | 0.89 | MAOB (0.59) | MAOBKDM4EALDH1A1SMN1; SMN2ESR1 | |
| Hydrochloric Acid SCHEMBL5935445 | 0.86 | HRH3 (0.60) | MAOBKDM4EALDH1A1SMN1; SMN2ESR1 | |
| Hydrochloric Acid SCHEMBL5935375 | 0.83 | MAOB (0.60) | MAOBKDM4EALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL27878428 | 0.83 | MAOB (0.77) | MAOBKDM4EALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4224579 | 0.82 | KDM4E (0.67) | MAOBKDM4EALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL4233027 | 0.82 | HRH3 (0.55) | MAOBKDM4EALDH1A1SMN1; SMN2HRH3 | |
| Hydrochloric Acid SCHEMBL5935382 | 0.82 | HRH3 (0.53) | MAOBESR1ESR2HRH3 | |
| Hydrochloric Acid SCHEMBL4224438 | 0.81 | HRH3 (0.54) | MAOBKDM4EALDH1A1SMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042862-A1 | NOVEL COMPOUNDS | BEST DESMOND JOHN | 2009-02-12 | — | — | US | disclosed |
| US-7446103-B2 | Bicyclic benzamide compound as histamine H3 receptor ligand useful in the treatment of neurological diseases | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| EP-1554243-B1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20060052597-A1 | Aryloxyalkylamine derivatives as h3 receptor ligands | BEST DESMOND J | 2006-03-09 | — | — | US | disclosed |
| EP-1554243-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| EP-1554260-A1 | ARYLOXYALKYLAMINE DERIVATIVES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037800-A1 | ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | HRH3, HRH4, HRH1 | MAOB 201/4885KDM4E 1909/4885ALDH1A1 2111/4885 |
| US-20060052597-A1 | Aryloxyalkylamine derivatives as h3 receptor ligands | HRH3, HTR6, HTR4 | MAOB 210/4885KDM4E 563/4885ALDH1A1 1017/4885 |
| US-20090042862-A1 | NOVEL COMPOUNDS | GRIN2C, GRIN2A, GRIN2B | MAOB 29/4885KDM4E 1950/4885ALDH1A1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.